Bench to Bedside at AI Speed

Why It Matters

Accelerating patient recruitment shortens drug development timelines and improves trial representativeness, directly impacting therapeutic access and market entry speed. AI-driven recruitment also reduces costs and mitigates bias in clinical research.

Key Takeaways

• RECTIFIER uses RAG to automate inclusion/exclusion review.
• AIwithCare cuts patient screening time by up to 70%.
• Tool improves trial diversity by identifying under‑represented groups.
• Scalable AI matches patients to therapies across large health systems.

Pulse Analysis

The biggest hurdle in modern drug development is finding the right patients quickly enough to keep trials on schedule. Traditional manual chart reviews are labor‑intensive, error‑prone, and often miss eligible participants from underserved populations. AI platforms like AIwithCare’s RECTIFIER apply Retrieval‑Augmented Generation to parse millions of electronic health records, extracting eligibility criteria and flagging candidates in minutes rather than weeks. This shift not only speeds enrollment but also creates a data‑driven foundation for precision medicine, allowing sponsors to target therapies to the patients most likely to benefit.

RECTIFIER’s core innovation lies in its RAG architecture, which combines large language models with a curated medical knowledge base. By grounding AI outputs in verified clinical data, the system can evaluate complex inclusion and exclusion rules—such as comorbidities, lab thresholds, and prior medication histories—without hallucination. Early pilots report a 70% reduction in screening time and a 30% increase in enrollment of under‑represented demographics, addressing regulatory pressures for trial diversity. The platform also integrates with existing hospital information systems, ensuring seamless workflow adoption and maintaining patient privacy through de‑identified data pipelines.

Industry analysts see AI‑enhanced trial infrastructure as a catalyst for faster, cheaper drug approvals. As the FDA and EMA encourage real‑world evidence, tools like RECTIFIER enable sponsors to generate robust, representative datasets that satisfy regulatory scrutiny. Moreover, scalable AI matching can be extended beyond trials to post‑market surveillance and personalized therapy allocation, reshaping the entire continuum of care. Companies that adopt such technology early stand to gain competitive advantage through reduced time‑to‑market and stronger therapeutic positioning.

Original Description

How can AI determine who gets matched to new therapies, who is identified for clinical trials, and how patient tracking is scaled across large populations? Chip is joined by Dr. A.J. Blood, a practicing cardiologist at Brigham and Women's Hospital and the co-founder and Chief Executive Officer of AIwithCare, a startup company that delivers AI-enabled solutions for research, clinical operations, and patient care. They discuss the role of AI in identifying patients for clinical trials and new therapies—which is typically a critical bottleneck in drug development—as well as how to ensure clinical trials are representative. Also, Dr. Blood shares insights from his extensive research background and the tool, RECTIFIER (RAG-Enabled Clinical Trial Infrastructure for Inclusion Exclusion Review), designed to enhance patient recruitment for clinical trials by efficiently sifting through complex medical data.